Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konstantin H Dragnev

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|June 17, 2024
Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?Sai Yendamuri, Konstantin H Dragnev
The Oncologist|January 6, 2005
Emerging role of rexinoids in non-small cell lung cancer: focus on bexaroteneJames R Rigas, Konstantin H Dragnev
Chest|January 16, 2003
Lung cancer prevention: the guidelinesKonstantin H Dragnev, Diane Stover, Ethan Dmitrovsky, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Cyclin D1 as a target for chemopreventionW Jeffrey Petty, Konstantin H Dragnev, Ethan Dmitrovsky
Cancer Biology & Therapy|September 26, 2003
Retinoid targets in cancer therapy and chemopreventionKonstantin H Dragnev, W Jeffrey Petty, Ethan Dmitrovsky
Seminars in Oncology|July 15, 2005
Docetaxel in the treatment of esophageal cancerJames R Rigas, Konstantin H Dragnev, Jeffrey A Bubis
Expert Opinion on Pharmacotherapy|May 8, 2010
Pemetrexed in advanced non-small-cell lung cancerAlexander D Fuld, Konstantin H Dragnev, James R Rigas
Frontiers in Cell and Developmental Biology|May 11, 2023
Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitationsKonstantin H Dragnev, Christo P C Dragnev, Ronald A Lubet
Clinical Pharmacology : Advances and Applications|February 19, 2019
Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapyWilliam G North, Fuli Liu, Konstantin H Dragnev, et al.
Cancer Treatment Reviews|June 18, 2013
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patientsMonic Roengvoraphoj, Gregory J Tsongalis, Konstantin H Dragnev, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Cancer Prevention Research (Philadelphia, Pa.)|June 17, 2024
Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?Sai Yendamuri, Konstantin H Dragnev
The Oncologist|January 6, 2005
Emerging role of rexinoids in non-small cell lung cancer: focus on bexaroteneJames R Rigas, Konstantin H Dragnev
Chest|January 16, 2003
Lung cancer prevention: the guidelinesKonstantin H Dragnev, Diane Stover, Ethan Dmitrovsky, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Cyclin D1 as a target for chemopreventionW Jeffrey Petty, Konstantin H Dragnev, Ethan Dmitrovsky
Cancer Biology & Therapy|September 26, 2003
Retinoid targets in cancer therapy and chemopreventionKonstantin H Dragnev, W Jeffrey Petty, Ethan Dmitrovsky
Seminars in Oncology|July 15, 2005
Docetaxel in the treatment of esophageal cancerJames R Rigas, Konstantin H Dragnev, Jeffrey A Bubis
Expert Opinion on Pharmacotherapy|May 8, 2010
Pemetrexed in advanced non-small-cell lung cancerAlexander D Fuld, Konstantin H Dragnev, James R Rigas
Frontiers in Cell and Developmental Biology|May 11, 2023
Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitationsKonstantin H Dragnev, Christo P C Dragnev, Ronald A Lubet
Clinical Pharmacology : Advances and Applications|February 19, 2019
Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapyWilliam G North, Fuli Liu, Konstantin H Dragnev, et al.
Cancer Treatment Reviews|June 18, 2013
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patientsMonic Roengvoraphoj, Gregory J Tsongalis, Konstantin H Dragnev, et al.
Pageof 7